(19)
(11) EP 4 798 225 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24798236.6

(22) Date of filing: 25.10.2024
(51) International Patent Classification (IPC): 
A61K 38/28(2006.01)
A61P 35/00(2006.01)
 A61K 38/50(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/50; A61K 38/28; A61P 35/00; C12Y 305/01001; C12Y 305/03001; A61K 38/53; C12Y 603/04005; C12Y 305/01002
 
C-Sets:
A61K 38/28, A61K 2300/00;
(86) International application number:
PCT/EP2024/080235
(87) International publication number:
WO 2025/088121 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 27.10.2023 EP 23206427

(71) Applicant: Kyon Biotech AG
8005 Zürich (CH)

(72) Inventors:
  • TEPIC, Slobodan
    8057 Zürich (CH)
  • CVETKOVIC, Goran
    8645 Jona (CH)
  • CVETKOVIC, Olivera
    8645 Jona (CH)

(74) Representative: Weickmann & Weickmann PartmbB 
Richard-Strauss-Strasse 80
81679 München
81679 München (DE)

   


(54) COMBINED ENZYMATIC-METABOLIC CANCER THERAPY